A31 MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY-TO-SEVERELY ACTIVE UC: IMPROVEMENT IN IBDQ SCORES IN PARTICIPANTS OF LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS

BACKGROUND: The inflammatory bowel disease questionnaire (IBDQ) is a measure of health-related quality of life (QoL), with higher scores indicating greater QoL. In a prior phase 2 study (NCT02589665), mirikizumab, an anti-IL23p19 antibody, demonstrated efficacy and improvement in IBDQ scores in part...

Descripción completa

Detalles Bibliográficos
Autores principales: Sands, B E, Feagan, B, Gibble, T H, Traxler, K A, Morris, N, Li, X, Schreiber, S, Jairath, V, Armuzzi, A, Jones, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Poster of Distinction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991148/
http://dx.doi.org/10.1093/jcag/gwac036.031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991148/
http://dx.doi.org/10.1093/jcag/gwac036.031

Ejemplares similares